Enzyme kinetics and distinct modulation of the protein kinase N family of kinases by lipid activators and small molecule inhibitors

por Falk, Matthew D., Liu, Wei, Bolaños, Ben, Unsal-Kacmaz, Keziban, Klippel, Anke, Grant, Stephan, Brooun, Alexei, Timofeevski, Sergei
Publicado 2014

Adjuvant nivolumab versus placebo following radical surgery for high-risk muscle-invasive urothelial carcinoma: a subgroup analysis of Japanese patients enrolled in the phase 3 Che...

por Tomita, Yoshihiko, Kobayashi, Ko, Kimura, Go, Oya, Mototsugu, Uemura, Hirotsugu, Nishiyama, Hiroyuki, Galsky, Matthew D, Nasroulah, Federico, Collette, Sandra, Broughton, Edward, Ünsal-Kaçmaz, Keziban, Kamisuki, Yukinori, Bajorin, Dean F
Publicado 2022

BMS-986158, a Small Molecule Inhibitor of the Bromodomain and Extraterminal Domain Proteins, in Patients with Selected Advanced Solid Tumors: Results from a Phase 1/2a Trial

por Hilton, John, Cristea, Mihaela, Postel-Vinay, Sophie, Baldini, Capucine, Voskoboynik, Mark, Edenfield, William, Shapiro, Geoffrey I., Cheng, Michael L., Vuky, Jacqueline, Corr, Bradley, Das, Sharmila, Apfel, Abraham, Xu, Ke, Kozicki, Martin, Ünsal-Kaçmaz, Keziban, Hammell, Amy, Wang, Guan, Ravindran, Palanikumar, Kollia, Georgia, Esposito, Oriana, Coker, Shodeinde, Diamond, Jennifer R.
Publicado 2022

The hexosamine biosynthesis pathway is a targetable liability in KRAS/LKB1-mutant lung cancer

por Kim, Jiyeon, Lee, Hyun Min, Cai, Feng, Ko, Bookyung, Yang, Chendong, Lieu, Elizabeth L., Muhammad, Nefertiti, Rhyne, Shawn, Li, Kailong, Haloul, Mohamed, Gu, Wen, Faubert, Brandon, Kaushik, Akash K., Cai, Ling, Kasiri, Sahba, Marriam, Ummay, Nham, Kien, Girard, Luc, Wang, Hui, Sun, Xiankai, Kim, James, Minna, John D., Unsal-Kacmaz, Keziban, DeBerardinis, Ralph J.
Publicado 2020

CPS1 maintains pyrimidine pools and DNA synthesis in KRAS/LKB1-mutant lung cancer cells

por Kim, Jiyeon, Hu, Zeping, Cai, Ling, Li, Kailong, Choi, Eunhee, Faubert, Brandon, Bezwada, Divya, Rodriguez-Canales, Jaime, Villalobos, Pamela, Lin, Yu-Fen, Ni, Min, Huffman, Kenneth E., Girard, Luc, Byers, Lauren A., Unsal-Kacmaz, Keziban, Peña, Christopher G., Heymach, John V., Wauters, Els, Vansteenkiste, Johan, Castrillon, Diego H., Chen, Benjamin P.C., Wistuba, Ignacio, Lambrechts, Diether, Xu, Jian, Minna, John D., DeBerardinis, Ralph J.
Publicado 2017

Nivolumab plus rucaparib for metastatic castration-resistant prostate cancer: results from the phase 2 CheckMate 9KD trial

por Fizazi, Karim, Retz, Margitta, Petrylak, Daniel P, Goh, Jeffrey C, Perez-Gracia, Jose, Lacombe, Louis, Zschäbitz, Stefanie, Burotto, Mauricio, Mahammedi, Hakim, Gravis, Gwenaelle, Bastos, Diogo Assed, McCune, Steven L, Vázquez Limón, Juan Carlos, Kwan, Edmond M, Castellano, Daniel, Fléchon, Aude, Saad, Fred, Grimm, Marc-Oliver, Shaffer, David R, Armstrong, Andrew J, Bhagavatheeswaran, Prabhu, Amin, Neha P, Ünsal-Kaçmaz, Keziban, Wang, Xuya, Li, Jun, Loehr, Andrea, Pachynski, Russell K
Publicado 2022